Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems.
AffiliationDepartment of Endocrinology, Christie Hospital, Wilmslow Road, Withington, Manchester, M20 4BX.
MetadataShow full item record
AbstractBACKGROUND: The prevalence of gallstones (GS) is increased in acromegaly and further increased by somatostatin analogue (SA) therapy. The incidence is reported at 10-63%, but they are often asymptomatic and rarely require definitive management. Evidence suggests discontinuation of SA may precipitate acute biliary problems. OBJECTIVE: To determine the frequency of symptomatic gallstones in patients treated with SA. DESIGN: Retrospective analysis of prospectively followed patients in our centre. RESULTS: Fifty patients (30 male, mean age 54 +/- 16 years) were on treatment with SA on 1 January 2003. Fifteen (11 male, mean age 50 +/- 17 years) have since discontinued SA with three proceeding to develop acute cholecystitis and two, biliary colic necessitating cholecystectomy. Three of the five had abnormal liver enzymes at or within 3 months of symptomatic presentation. Two of the remaining 35 patients experienced biliary colic necessitating cholecystectomy. These data indicate a highly significant increase in acute biliary problems on discontinuing SA (5 in 27.67 patient 'off-treatment' years vs. 2 in 299 patient treatment years, chi(2), P < 0.0001). All seven patients experiencing problems were male (P = 0.01). CONCLUSION: This analysis demonstrates the high incidence of symptomatic GS following SA withdrawal, particularly in men. Although liver enzymes were raised no common abnormality was evident to aid as a predictor of future symptoms. We recommend all patients due to stop SA be forewarned of the risk of acute biliary problems. Further work is required to confirm if there is a gender-related difference in the incidence of acute biliary problems on discontinuing SA therapy.
CitationWithdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. 2007, 66 (5):723-6 Clin. Endocrinol.
- Is withdrawal of somatostatin analogue therapy in patients with acromegaly associated with an increased risk of acute biliary problems?
- Authors: Ng CM, Shek CC, Choi CH, Tiu SC
- Issue date: 2008 Jan
- Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.
- Authors: Attanasio R, Mainolfi A, Grimaldi F, Cozzi R, Montini M, Carzaniga C, Grottoli S, Cortesi L, Albizzi M, Testa RM, Fatti L, De Giorgio D, Scaroni C, Cavagnini F, Loli P, Pagani G, Ghigo E
- Issue date: 2008 Aug
- [Novel pharmacologic therapies in acromegaly].
- Authors: Góth M, Hubina E, Kovács L, Szabolcs I
- Issue date: 2002 May 12
- Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
- Authors: Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ
- Issue date: 2009 Apr
- Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
- Authors: Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C
- Issue date: 2002 Jan